Dendritic cell vaccine (Medigene)

N/A

Report date: 2024/11/02 20:00:07

Base Information

Drug NameDendritic cell vaccine (Medigene)
Drug Alias NameDC vaccine,DC Vaccine for AML,DC Vaccine for prostate cancer,Leukemia-associated RNA transfected autologous dendritic cell vaccineCVT-DC-01IL-12p70 DC vaccineCD-FDC-001FDC-101 +[6] 
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNorwayGermany
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTrianta Immunotherapies
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLudwig Maximilians University Of MunichMedigene Ag
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A